ArticleVeterinary medicine and science2016
A phase I clinical study to evaluate safety of orally administered, genetically engineered
Article in Veterinary medicine and science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 64 citations in OpenAlex.
- A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer.Cancer immunology, immunotherapy : CII · 2026Trial
- Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits.Journal of hematology & oncology · 2025Review
- Article
- A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments.Applied biosafety : journal of the American Biological Safety Association · 2024Review
- Surface nanocoating of bacteria as a versatile platform to develop living therapeutics.Nature protocols · 2024Review
- Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy?Critical reviews in microbiology · 2024Review
- Bacterial derivatives mediated drug delivery in cancer therapy: a new generation strategy.Journal of nanobiotechnology · 2024Review
- A Review on Canine and Human Soft Tissue Sarcomas: New Insights on Prognosis Factors and Treatment Measures.Veterinary sciences · 2024Review
- Hypoxia-targeting bacteria in cancer therapy.Seminars in cancer biology · 2024Review
- A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.International journal of molecular sciences · 2024Review
- Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer.NPJ biofilms and microbiomes · 2024Article
- Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy.Frontiers in bioengineering and biotechnology · 2024Review
- Potential role of intratumor bacteria outside the gastrointestinal tract: More than passengers.Cancer medicine · 2023Review
- BSA modification of bacterial surface: a promising anti-cancer therapeutic strategy.BMC microbiology · 2023Article
- Review
- Ursolic acid-enriched kudingcha extract enhances the antitumor activity of bacteria-mediated cancer immunotherapy.BMC complementary medicine and therapies · 2022Article
- Engineered microorganism-based delivery systems for targeted cancer therapy: a narrative review.Biomaterials translational · 2022Review
- Bacteria-Based Synergistic Therapy in the Backdrop of Synthetic Biology.Frontiers in oncology · 2022Review
- Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines · 2021Review
- Highlights of Immunomodulation inBiomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a prospective phase I study to evaluate safety of an orally administered
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.